Sepsis Clinical Trial
— ASTROSOfficial title:
Adapting a Sepsis Transition and Recovery Program for Optimal Scale Up (ASTROS)
The Adapting a Sepsis Transition and Recovery Program for Optimal Scale Up (ASTROS) study is an effectiveness-implementation hybrid design. The effectiveness evaluation is designed as a multiple interrupted time series (mITS) analysis to test the impact of implementing an adapted Sepsis Transition and Recovery (STAR) program on enhancing post sepsis outcomes in new hospital settings.
Status | Recruiting |
Enrollment | 1280 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adults 18 years of age and older; - clinically suspected infection 1. two or more markers of systemic inflammatory response syndrome within 24 h of presentation; AND 2. antibiotics initiated within 24 hours and continued for at least one additional day - organ dysfunction 1. two or more points on admission Sequential Organ Failure Assessment (SOFA); OR 2. two or more points on admission quick-SOFA - deemed to be at high risk of hospital readmission within 90 days, defined as readmission risk probability of at least 25% - not discharged from the hospital at the time of patient identification each morning. Exclusion Criteria: - change in code status (i.e., initially full code followed by change to do not resuscitate and/or do not intubate) within 24 hours after index presentation due to presumed limitation of aggressive treatment and exposure to STAR program components; - reside > 2.5 hours drive time from the treating hospital due to the maximum reach of the community services leveraged within the STAR program and the general assumption that these patients may have less comprehensive utilization tracking within available electronic record systems for study outcomes; - are actively participating in a different care management program (e.g., cancer care patient navigation) documented in the electronic health record (EHR) at time of hospital admission. |
Country | Name | City | State |
---|---|---|---|
United States | Atrium Health | Charlotte | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | The Duke Endowment |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Qualitative assessment of the core functions of the STAR program | Open-ended, qualitative evaluation to identify core functions necessary to maintain program effectiveness when implementing the STAR program in new settings | Pre-implementation | |
Other | Qualitative assessment of the adaptable "forms" for implementing the STAR program | Open-ended, qualitative evaluation to identify potential adaptations that are important to implementing the STAR program in new settings | Pre-implementation | |
Other | Number of providers included in STAR program adoption | Number of hospital attending providers with patients enrolled in STAR | Up to 2 years | |
Other | Number of eligible patients reached by STAR program | Total number of patients who received the intervention | Up to 2 years | |
Other | Proportion of patients with STAR program intervention delivered as intended | Quantitative assessment of fidelity to completion of key intervention components (e.g., medication reconciliation, physical and mental health screenings, goals-of-care documentation) | Up to 2 years | |
Primary | All-cause mortality and hospital readmission rate | Binary composite endpoint of mortality and hospital readmission assessed 90 days post index hospital discharge | day 90 | |
Secondary | Number of hospital free days | Continuous composite endpoint of days alive and outside of the hospital assessed 90 days post index hospital discharge | day 90 | |
Secondary | All-cause mortality rate | Binary endpoint of all-cause mortality rate assessed 90 days post index hospital discharge | day 90 | |
Secondary | All-cause hospital readmission rate | Binary endpoint of all-cause readmission rate assessed 90 days post index hospital discharge | day 90 | |
Secondary | Acute care-related costs | Healthcare costs attributed to care received at emergency department, observation, and inpatient encounters during follow-up | day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |